Polyarteritis nodosa is an unforeseen borderline paradoxical adverse reaction in a female patient with rheumatoid arthritis treated with tofacitinib
https://doi.org/10.14412/1996-7012-2019-3-142-143
Abstract
The paper describes the occurrence of polyarteritis nodosa in a patient with rheumatoid arthritis during treatment with tofacitinib. It considers the reasons why this condition should be regarded as an unforeseen borderline paradoxical adverse reaction.
About the Authors
Yu. V. Muraviev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Yuri Vladimirovich Muraviev.
34A, Kashirskoe Shosse, Moscow 115522.
S. G. Radenska-Lopovok
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
11, Rossilimo St., Build. 1, Moscow 119021.
V. V. Lebedeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
S. Yu. Alamankina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
References
1. Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. 2014 May;73(5):871-82. doi: 10.1136/annrheumdis-2012-203116. Epub 2013 Apr 18.
2. He Y, Wong AY, Chan EW, et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis BMC Musculoskelet Disord. 2013 Oct 18;14:298. doi: 10.1186/1471-2474-14-298.
3. Singh JA, Hossain A, Tanjong Ghogomu E,et al. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Cochrane Database Syst Rev. 2016 Nov 17; 11:CD012437.
4. Toussirot Г, Aubin F. Paradoxical reactions under TNF-а blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016 Jul 15;2(2):e000239. doi: 10.1136/rmdopen-2015-000239. eCollection 2016.
5. Viguier M, Richette P, Bachelez H, et al. Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol. 2009 Jul;5(4):421-31. doi: 10.1586/eci.09.18.
6. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30(2): 239-45.
7. Rimar D, Alpert A, Starosvetsky E, et al. Tofacitinib for polyarteritis nodosa: a tailored therapy. Ann Rheum Dis. 2016 Dec;75(12):2214-2216. doi: 10.1136/annrheumdis-2016-209330. Epub 2016 Aug 24.
Review
For citations:
Muraviev YV, Radenska-Lopovok SG, Lebedeva VV, Alamankina SY. Polyarteritis nodosa is an unforeseen borderline paradoxical adverse reaction in a female patient with rheumatoid arthritis treated with tofacitinib. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2019;13(3):142-143. (In Russ.) https://doi.org/10.14412/1996-7012-2019-3-142-143
Views:
953
Email this article 